Entering text into the input field will update the search result below

Eyenovia rises on positive data from Optejet delivery technology trial

  • Eyenovia (NASDAQ:EYEN) is trading ~5% higher premarket after it announced positive results from a research study that showed Optejet delivery technology decreased inflammation from preserved glaucoma solutions compared to drops.
  • The study evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment was administered via Optejet versus latanoprost+BAK administered via standard eye drops.

Recommended For You

About EYEN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EYEN--
Eyenovia, Inc.